Jan Skvarka insider trades

Open-market stock purchases and sales by Jan Skvarka, Director at Zentalis Pharmaceuticals, Inc, from SEC Form 4 filings since Jan 13, 2021.

Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +115%.

Recent trades

DateStockTradeValue
Jun 16, 2026ZNTL Zentalis Pharmaceuticals, IncBought (not open market)—
Jun 11, 2026GLUE Monte Rosa Therapeutics, IncBought (not open market)—

Companies traded

  • ZNTL Zentalis Pharmaceuticals, Inc: 1 buy, 1 sale, last Jun 16, 2026
  • GLUE Monte Rosa Therapeutics, Inc: other filings, last Jun 11, 2026
  • TRIL Trillium Therapeutics Inc: 4 sales, last Nov 17, 2021

Get free alerts when Jan Skvarka files a new trade →